Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral hemorrhage, central nervous system infection)~* Parental informed consent (in-person or remote consent)~* Undergoing continuous video electroencephalogram (cvEEG) monitoring~* Has evidence of electrographic seizure burden of at least 30 seconds/h~Exclusion Criteria:~* Received anticonvulsant treatment, including phenobarbital, prior to randomization (with exception of lorazepam administered for sedation \> 24 hours before enrollment)~* Strong suspicion or confirmed diagnosis of brain malformation, inborn error of metabolism genetic syndrome, or major congenial malformation prior to randomization~* Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic disorder~* Death appears to be imminent as assessed by the NICU attending physician~* Is currently enrolled in another study assessing the same and/or similar primary/secondary endpoints with/without drug treatment.

- Gender: ALL
- Minimum Age: 34 Weeks
- Maximum Age: 44 Weeks
- Healthy Volunteers: f

Study Arms:
- Phenobarbital Sodium Injection 20mg (Type: ACTIVE_COMPARATOR): Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
- Phenobarbital Sodium Injection 40mg (Type: ACTIVE_COMPARATOR): Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).

Based on this trial design, predict the completion outcome and termination type (if applicable).